DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor  + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma

ConclusionSingle-agent belamaf represents a new treatment option for triple-class refractory patients with RRMM.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research